These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 18957881)

  • 1. Lipid lowering in the patients with prediabetes/metabolic syndrome: what is the evidence?
    Steiner G
    Curr Opin Lipidol; 2008 Dec; 19(6):585-91. PubMed ID: 18957881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes.
    Jones MR; Mudaliar S; Hernandez-Triana E; Unnikrishnan AG; Lai YL; Abby SL; Misir S; Jin X; Nagendran S
    Curr Med Res Opin; 2009 Sep; 25(9):2239-49. PubMed ID: 19622007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysglycaemia in non-diabetic hypertensive patients: comparison of the impact of two different classifications of impaired fasting glucose on the cardiovascular risk profile.
    Dell'Omo G; Penno G; Del Prato S; Mariani M; Pedrinelli R
    J Hum Hypertens; 2009 May; 23(5):332-8. PubMed ID: 19078990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid lowering in diabetes mellitus.
    Betteridge DJ
    Curr Opin Lipidol; 2008 Dec; 19(6):579-84. PubMed ID: 18957880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.
    Winkler UH; Sudik R
    Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic syndrome, prediabetes and the science of primary prevention.
    Nyenwe EA; Dagogo-Jack S
    Minerva Endocrinol; 2011 Jun; 36(2):129-45. PubMed ID: 21519322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for optimizing lipid management.
    Ballantyne CM
    Postgrad Med; 2004 Sep; 116(3 Suppl):13-20. PubMed ID: 19667671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid and lipoprotein metabolism in chronic kidney disease.
    Kaysen GA
    J Ren Nutr; 2009 Jan; 19(1):73-7. PubMed ID: 19121776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH
    Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low plasma HDL-c, a vascular risk factor in high risk patients independent of LDL-c.
    Hajer GR; van der Graaf Y; Bots ML; Algra A; Visseren FL;
    Eur J Clin Invest; 2009 Aug; 39(8):680-8. PubMed ID: 19453647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study to find out the proportion of prediabetes in patients with acute coronary syndrome in a medical college of Kolkata.
    Sen K; Mukherjee AK; Dharchowdhury L; Chatterjee A
    J Indian Med Assoc; 2008 Dec; 106(12):776-8. PubMed ID: 19370946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular risk assessment in prediabetes: A hypothesis.
    Nwose EU; Richards RS; Cann NG; Butkowski E
    Med Hypotheses; 2009 Mar; 72(3):271-5. PubMed ID: 19042094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study.
    Andreadis EA; Katsanou PM; Georgiopoulos DX; Tsourous GI; Yfanti GK; Gouveri ET; Diamantopoulos EJ
    Exp Clin Endocrinol Diabetes; 2009 Apr; 117(4):175-80. PubMed ID: 19053032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of antidiabetic drugs on genes regulating lipid metabolism.
    Tomkin GH
    Curr Opin Lipidol; 2009 Feb; 20(1):10-6. PubMed ID: 19106706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum lipid and hsCRP levels in prediabetes--impaired fasting glucose (IFG) and impaired glucose tolerance (IGT).
    Chakarova N; Tankova T; Atanassova I; Dakovska L
    Diabetes Res Clin Pract; 2009 Oct; 86(1):56-60. PubMed ID: 19674805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes.
    Roman G; Hancu N
    Horm Metab Res; 2009 Feb; 41(2):116-22. PubMed ID: 19214921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating dyslipidemia in high-risk patients: case reviews and discussion.
    Deedwania PC; Davidson MH; Ballantyne CM
    Postgrad Med; 2004 Sep; 116(3 Suppl):21-8. PubMed ID: 19667672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2.
    Santos RD; Waters DD; Tarasenko L; Messig M; Jukema JW; Ferrières J; Verdejo J; Chiang CW;
    Am Heart J; 2009 Nov; 158(5):860-6. PubMed ID: 19853709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological intervention in prediabetes: considering the risks and benefits.
    Del Prato S; Bianchi C; Miccoli R; Penno G
    Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():17-22. PubMed ID: 17877543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.